|Bid||41.80 x 1000|
|Ask||42.29 x 1000|
|Day's range||41.09 - 44.78|
|52-week range||13.84 - 100.00|
|Beta (5Y monthly)||0.52|
|PE ratio (TTM)||N/A|
|Earnings date||08 Nov 2022 - 14 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||13 Dec 2012|
|1y target est||69.00|
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $43.07, moving -1.76% from the previous trading session.
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $31.04, moving -1.71% from the previous trading session.
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held in New York. Remi Barbier, President & CEO, will participate in-person at this corporate event. Institutional investors who are registered for this conference may log into www.hcwevents.com t